ETOMIDATE

Etomidate Adverse Events Reported to the FDA Over Time

How are Etomidate adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Etomidate, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Etomidate is flagged as the suspect drug causing the adverse event.

Most Common Etomidate Adverse Events Reported to the FDA

What are the most common Etomidate adverse events reported to the FDA?

Bradycardia	24 (3.57%)
Drug Exposure During Pregnancy	19 (2.82%)
Cardiac Arrest	18 (2.67%)
Hypotension	18 (2.67%)
Anaphylactic Shock	16 (2.38%)
Blood Pressure Decreased	11 (1.63%)
Convulsion	10 (1.49%)
Drug Ineffective	10 (1.49%)
Tachycardia	10 (1.49%)
Ventricular Tachycardia	10 (1.49%)
Drug Interaction	9 (1.34%)
	Show More
Myoclonus	9 (1.34%)
Bronchospasm	7 (1.04%)
Cardiovascular Disorder	7 (1.04%)
Grand Mal Convulsion	7 (1.04%)
Oxygen Saturation Decreased	6 (.89%)
Post Procedural Complication	6 (.89%)
Cardio-respiratory Arrest	5 (.74%)
Coma	5 (.74%)
Dyspnoea	5 (.74%)
Erythema	5 (.74%)
Hepatitis Toxic	5 (.74%)
Injection Site Phlebitis	5 (.74%)
Live Birth	5 (.74%)
Lung Disorder	5 (.74%)
Medication Error	5 (.74%)
Urticaria	5 (.74%)
Agitation	4 (.59%)
Anaesthetic Complication	4 (.59%)
Haemodynamic Instability	4 (.59%)
Heart Rate Increased	4 (.59%)
Loss Of Consciousness	4 (.59%)
Overdose	4 (.59%)
Procedural Complication	4 (.59%)
Pyrexia	4 (.59%)
Respiratory Failure	4 (.59%)
Toxic Skin Eruption	4 (.59%)
Ventricular Fibrillation	4 (.59%)
Anaphylactic Reaction	3 (.45%)
Aspiration	3 (.45%)
Atrial Fibrillation	3 (.45%)
Body Temperature Increased	3 (.45%)
C-reactive Protein Increased	3 (.45%)
Cardiovascular Insufficiency	3 (.45%)
Dermatitis Bullous	3 (.45%)
Dermatomyositis	3 (.45%)
Dysphagia	3 (.45%)
Electromechanical Dissociation	3 (.45%)
Hyperthermia	3 (.45%)
Ischaemic Hepatitis	3 (.45%)
Leg Amputation	3 (.45%)
Lymphocele	3 (.45%)
Lymphopenia	3 (.45%)
Monoplegia	3 (.45%)
Mood Altered	3 (.45%)
Neoplasm	3 (.45%)
No Therapeutic Response	3 (.45%)
Nodule	3 (.45%)
Normochromic Normocytic Anaemia	3 (.45%)
Operative Haemorrhage	3 (.45%)
Peripheral Ischaemia	3 (.45%)
Pityriasis	3 (.45%)
Proteinuria	3 (.45%)
Prurigo	3 (.45%)
Rales	3 (.45%)
Rash	3 (.45%)
Renal Impairment	3 (.45%)
Respiratory Arrest	3 (.45%)
Skin Necrosis	3 (.45%)
Adrenocortical Insufficiency Acute	2 (.3%)
Airway Complication Of Anaesthesia	2 (.3%)
Altered State Of Consciousness	2 (.3%)
Aortic Valve Incompetence	2 (.3%)
Apgar Score Low	2 (.3%)
Apnoea	2 (.3%)
Arrhythmia	2 (.3%)
Asthenia	2 (.3%)
Blood Bilirubin Increased	2 (.3%)
Brain Oedema	2 (.3%)
Bronchial Obstruction	2 (.3%)
Caesarean Section	2 (.3%)
Cardiac Failure	2 (.3%)
Cardiomegaly	2 (.3%)
Cholecystitis	2 (.3%)
Circulatory Collapse	2 (.3%)
Cyanosis	2 (.3%)
Death	2 (.3%)
Diabetes Mellitus Inadequate Contro...	2 (.3%)
Disease Recurrence	2 (.3%)
Electrocardiogram St Segment Elevat...	2 (.3%)
Eyelid Oedema	2 (.3%)
Haemoconcentration	2 (.3%)
Haemorrhage	2 (.3%)
Heart Rate Decreased	2 (.3%)
Hypercapnia	2 (.3%)
Hyperhidrosis	2 (.3%)
Hypoventilation	2 (.3%)
Incorrect Dose Administered	2 (.3%)
Incorrect Route Of Drug Administrat...	2 (.3%)
Insomnia	2 (.3%)
Laryngeal Oedema	2 (.3%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Etomidate, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Etomidate is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Etomidate

What are the most common Etomidate adverse events reported to the FDA?

Cardiac Arrhythmias	90 (13.37%)
Epidermal And Dermal Conditions	34 (5.05%)
Respiratory	34 (5.05%)
Neurological	31 (4.61%)
Cardiac And Vascular Investigations	26 (3.86%)
Procedural And Device Related Injur...	26 (3.86%)
Decreased And Nonspecific Blood Pre...	25 (3.71%)
Therapeutic And Nontherapeutic Effe...	25 (3.71%)
Chemical Injury And Poisoning	22 (3.27%)
Allergic Conditions	21 (3.12%)
Seizures	19 (2.82%)
	Show More
Medication Errors	16 (2.38%)
Cardiac Disorder Signs	11 (1.63%)
Bronchial Disorders	10 (1.49%)
Administration Site Reactions	9 (1.34%)
Physical Examination Topics	9 (1.34%)
Depressed Mood Disorders	8 (1.19%)
Hepatic And Hepatobiliary	8 (1.19%)
Body Temperature Conditions	7 (1.04%)
Gastrointestinal Signs	7 (1.04%)
Metabolic, Nutritional And Blood Ga...	7 (1.04%)
Adrenal Gland	6 (.89%)
Movement Disorders	6 (.89%)
Renal Disorders	6 (.89%)
Angiedema And Urticaria	5 (.74%)
Glucose Metabolism Disorders	5 (.74%)
Myocardial	5 (.74%)
Pregnancy, Labour, Delivery And Pos...	5 (.74%)
Urinary Tract Signs	5 (.74%)
Anemias Nonhemolytic And Marrow Dep...	4 (.59%)
Anxiety Disorders	4 (.59%)
Cardiac Valve	4 (.59%)
Central Nervous System Vascular	4 (.59%)
Endocrine Investigations	4 (.59%)
Gallbladder	4 (.59%)
Heart Failures	4 (.59%)
Mood Disorders	4 (.59%)
Muscle	4 (.59%)
Neonatal And Perinatal Conditions	4 (.59%)
Neuromuscular	4 (.59%)
Sleep Disorders	4 (.59%)
Suicidal And Self-injurious Behavio...	4 (.59%)
Tissue	4 (.59%)
Toxicology And Therapeutic Drug Mon...	4 (.59%)
Vascular	4 (.59%)
White Blood Cell	4 (.59%)
Arteriosclerosis, Stenosis, Vascula...	3 (.45%)
Bone And Joint Therapeutic Procedur...	3 (.45%)
Hematological	3 (.45%)
Hematology Investigations	3 (.45%)
Injuries	3 (.45%)
Lower Respiratory Tract Disorders	3 (.45%)
Lymphatic Vessel	3 (.45%)
Miscellaneous And Site Unspecified ...	3 (.45%)
Protein And Chemistry Analyses	3 (.45%)
Upper Respiratory Tract Disorders	3 (.45%)
Bacterial Infectious	2 (.3%)
Deliria	2 (.3%)
Endocrine And Glandular	2 (.3%)
Fatal Outcomes	2 (.3%)
Hepatobiliary	2 (.3%)
Increased Intracranial Pressure And...	2 (.3%)
Infections - Pathogen Unspecified	2 (.3%)
Lifestyle Issues	2 (.3%)
Mental Impairment	2 (.3%)
Neurological, Special Senses And Ps...	2 (.3%)
Obstetric And Gynecological Therape...	2 (.3%)
Ocular Infections, Irritations And ...	2 (.3%)
Personality Disorders	2 (.3%)
Postpartum And Puerperal	2 (.3%)
Product Quality Issues	2 (.3%)
Skin Appendage Conditions	2 (.3%)
Skin Vascular Abnormalities	2 (.3%)
Therapeutic Procedures And Supporti...	2 (.3%)
Thoracic Disorders	2 (.3%)
Thyroid Gland	2 (.3%)
Uterine, Pelvic And Broad Ligament	2 (.3%)
Vascular Hemorrhagic	2 (.3%)
Vascular Inflammations	2 (.3%)
Acid-base	1 (.15%)
Aural	1 (.15%)
Bone And Joint Injuries	1 (.15%)
Changes In Physical Activity	1 (.15%)
Communication Disorders	1 (.15%)
Coronary Artery	1 (.15%)
Eating Disorders	1 (.15%)
Electrolyte And Fluid Balance Condi...	1 (.15%)
Embolism And Thrombosis	1 (.15%)
Gastrointestinal Hemorrhages	1 (.15%)
Gastrointestinal Motility And Defec...	1 (.15%)
Hearing	1 (.15%)
Hypothalamus And Pituitary Gland	1 (.15%)
Immunology And Allergy	1 (.15%)
Legal Issues	1 (.15%)
Maternal Complications Of Labour An...	1 (.15%)
Maternal Complications Of Pregnancy	1 (.15%)
Menopause And Related Conditions	1 (.15%)
Musculoskeletal And Connective Tiss...	1 (.15%)
Musculoskeletal And Connective Tiss...	1 (.15%)
Ocular Neuromuscular	1 (.15%)
Pericardial	1 (.15%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Etomidate, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Etomidate is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.